The Comparison of Interleukin 6-associated Immunosuppressive Effects of Human ESCs, Fetal-type MSCs, and Adult-type MSCs
Overview
Authors
Affiliations
Background: Although human embryonic stem cells (ESCs) and mesenchymal stem cells (MSCs) from various sources display immunomodulatory effects, direct comparisons among these classes of stem cells have not been reported.
Methods: Peripheral blood mononuclear cell suppression assays and carboxyfluorescein diacetate succinimidyl ester assays were used to assess the immunosuppressive effects of stem cells. Gene expression was measured using DNA microarrays. Enzyme-linked immunosorbent assays were used to determine interleukin (IL)-6 levels.
Results: We found that fetal-type MSCs proliferated significantly faster than adult-type MSCs. Compared with ESCs grown on feeder cells, ESCs grown in feeder cell-free conditions exhibited decreased immunosuppressive effects. The suppressive effects of ESCs were significantly stronger than those of MSCs, and the suppressive effects of fetal-type MSCs were significantly stronger than those of adult-type MSCs at each tested dose level. Analysis of gene expression by microarray and MetaCore pathway mapping revealed changes in eight different immune response pathways; we observed that IL-6 gene expression was highly significantly involved in all eight pathways. Significantly higher IL-6 elevation ratios (IL-6after:IL-6before) were found in ESCs compared with fetal-type MSCs, and these were also found in fetal-type MSCs compared with adult-type MSCs. Furthermore, IL-6 levels were found to correlate with cell dosages of MSCs and the suppressive effects.
Conclusions: The ease of obtaining fetal-type MSCs and their rapid proliferation make these cells ideal candidates for cell-based therapies, especially for diseases associated with immune responses, given the immunosuppressive effects of these cells. IL-6 might play an important role in the immunosuppressive effects of various stem cells.
Mesenchymal Stem Cells in the Treatment of COVID-19.
Guo B, Wu K, Chen C, Lin W, Chang Y, Lee T Int J Mol Sci. 2023; 24(19).
PMID: 37834246 PMC: 10573267. DOI: 10.3390/ijms241914800.
Mesenchymal Stem Cells in Acquired Aplastic Anemia: The Spectrum from Basic to Clinical Utility.
Wang X, Li J, Wu K, Yang S, Chao Y Int J Mol Sci. 2023; 24(5).
PMID: 36901900 PMC: 10003043. DOI: 10.3390/ijms24054464.
Yi H, Wang Y, Liang Q, Mao X Cell Transplant. 2022; 31:9636897211051743.
PMID: 35916286 PMC: 9350497. DOI: 10.1177/09636897211051743.
Li J, Wu K, Chao W, Lee Y, Yang S, Chao Y Int J Mol Sci. 2022; 23(15).
PMID: 35897770 PMC: 9331939. DOI: 10.3390/ijms23158196.
Wu K, Li J, Chao W, Lee Y, Yang S, Cheng C Int J Mol Sci. 2022; 23(10).
PMID: 35628107 PMC: 9141460. DOI: 10.3390/ijms23105295.